Cargando…

2,4-Dihydroxycinnamic acid as spike ACE2 inhibitor and apigenin as RdRp inhibitor in Nimbamritadi Panchatiktam Kashayam against COVID-19: an in silico and in vitro approach

Nimbamritadi Panchatiktam Kashayam (NPK) is an ayurvedic formulation composed of ingredients with potent anti-viral activities. We studied the interaction energy of 144 phytoconstituents present in NPK against spike receptor-binding domain (RBD) complexed with ACE2 protein (PDB ID: 6LZG) and RNA-dep...

Descripción completa

Detalles Bibliográficos
Autores principales: Murali, Maneesha, Nair, Bhagyalakshmi, Vishnu, V. R., Aneesh, T. P., Nath, Lekshmi R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9648999/
https://www.ncbi.nlm.nih.gov/pubmed/36357813
http://dx.doi.org/10.1007/s11030-022-10552-z
_version_ 1784827704203280384
author Murali, Maneesha
Nair, Bhagyalakshmi
Vishnu, V. R.
Aneesh, T. P.
Nath, Lekshmi R.
author_facet Murali, Maneesha
Nair, Bhagyalakshmi
Vishnu, V. R.
Aneesh, T. P.
Nath, Lekshmi R.
author_sort Murali, Maneesha
collection PubMed
description Nimbamritadi Panchatiktam Kashayam (NPK) is an ayurvedic formulation composed of ingredients with potent anti-viral activities. We studied the interaction energy of 144 phytoconstituents present in NPK against spike receptor-binding domain (RBD) complexed with ACE2 protein (PDB ID: 6LZG) and RNA-dependent RNA polymerase protein (PDB ID: 7BTF) using Biovia Drug Discovery studio. The result indicated that 2,4-hydroxycinnamic acid exerts more significant binding affinities (28.43 kcal/mol) than Umifenovir (21.24 kcal/mol) against spike ACE2. Apigenin exhibited the highest binding affinities (54.63 kcal/mol) compared with Remdesivir (24.52 kcal/mol) against RdRp. An in vitro analysis showed a reduction in the number of lentiviral particles on transfected HEK293T-hACE2 cells as assessed by pseudovirus inhibition assay. At the same time, the tested compounds showed non-toxic up to 100 µg/ml in normal cells by MTT assay. The study highlights the plausible clinical utility of this traditional medicine against SARS CoV2. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11030-022-10552-z.
format Online
Article
Text
id pubmed-9648999
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-96489992022-11-14 2,4-Dihydroxycinnamic acid as spike ACE2 inhibitor and apigenin as RdRp inhibitor in Nimbamritadi Panchatiktam Kashayam against COVID-19: an in silico and in vitro approach Murali, Maneesha Nair, Bhagyalakshmi Vishnu, V. R. Aneesh, T. P. Nath, Lekshmi R. Mol Divers Short Communication Nimbamritadi Panchatiktam Kashayam (NPK) is an ayurvedic formulation composed of ingredients with potent anti-viral activities. We studied the interaction energy of 144 phytoconstituents present in NPK against spike receptor-binding domain (RBD) complexed with ACE2 protein (PDB ID: 6LZG) and RNA-dependent RNA polymerase protein (PDB ID: 7BTF) using Biovia Drug Discovery studio. The result indicated that 2,4-hydroxycinnamic acid exerts more significant binding affinities (28.43 kcal/mol) than Umifenovir (21.24 kcal/mol) against spike ACE2. Apigenin exhibited the highest binding affinities (54.63 kcal/mol) compared with Remdesivir (24.52 kcal/mol) against RdRp. An in vitro analysis showed a reduction in the number of lentiviral particles on transfected HEK293T-hACE2 cells as assessed by pseudovirus inhibition assay. At the same time, the tested compounds showed non-toxic up to 100 µg/ml in normal cells by MTT assay. The study highlights the plausible clinical utility of this traditional medicine against SARS CoV2. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11030-022-10552-z. Springer International Publishing 2022-11-10 /pmc/articles/PMC9648999/ /pubmed/36357813 http://dx.doi.org/10.1007/s11030-022-10552-z Text en © The Author(s), under exclusive licence to Springer Nature Switzerland AG 2022 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Short Communication
Murali, Maneesha
Nair, Bhagyalakshmi
Vishnu, V. R.
Aneesh, T. P.
Nath, Lekshmi R.
2,4-Dihydroxycinnamic acid as spike ACE2 inhibitor and apigenin as RdRp inhibitor in Nimbamritadi Panchatiktam Kashayam against COVID-19: an in silico and in vitro approach
title 2,4-Dihydroxycinnamic acid as spike ACE2 inhibitor and apigenin as RdRp inhibitor in Nimbamritadi Panchatiktam Kashayam against COVID-19: an in silico and in vitro approach
title_full 2,4-Dihydroxycinnamic acid as spike ACE2 inhibitor and apigenin as RdRp inhibitor in Nimbamritadi Panchatiktam Kashayam against COVID-19: an in silico and in vitro approach
title_fullStr 2,4-Dihydroxycinnamic acid as spike ACE2 inhibitor and apigenin as RdRp inhibitor in Nimbamritadi Panchatiktam Kashayam against COVID-19: an in silico and in vitro approach
title_full_unstemmed 2,4-Dihydroxycinnamic acid as spike ACE2 inhibitor and apigenin as RdRp inhibitor in Nimbamritadi Panchatiktam Kashayam against COVID-19: an in silico and in vitro approach
title_short 2,4-Dihydroxycinnamic acid as spike ACE2 inhibitor and apigenin as RdRp inhibitor in Nimbamritadi Panchatiktam Kashayam against COVID-19: an in silico and in vitro approach
title_sort 2,4-dihydroxycinnamic acid as spike ace2 inhibitor and apigenin as rdrp inhibitor in nimbamritadi panchatiktam kashayam against covid-19: an in silico and in vitro approach
topic Short Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9648999/
https://www.ncbi.nlm.nih.gov/pubmed/36357813
http://dx.doi.org/10.1007/s11030-022-10552-z
work_keys_str_mv AT muralimaneesha 24dihydroxycinnamicacidasspikeace2inhibitorandapigeninasrdrpinhibitorinnimbamritadipanchatiktamkashayamagainstcovid19aninsilicoandinvitroapproach
AT nairbhagyalakshmi 24dihydroxycinnamicacidasspikeace2inhibitorandapigeninasrdrpinhibitorinnimbamritadipanchatiktamkashayamagainstcovid19aninsilicoandinvitroapproach
AT vishnuvr 24dihydroxycinnamicacidasspikeace2inhibitorandapigeninasrdrpinhibitorinnimbamritadipanchatiktamkashayamagainstcovid19aninsilicoandinvitroapproach
AT aneeshtp 24dihydroxycinnamicacidasspikeace2inhibitorandapigeninasrdrpinhibitorinnimbamritadipanchatiktamkashayamagainstcovid19aninsilicoandinvitroapproach
AT nathlekshmir 24dihydroxycinnamicacidasspikeace2inhibitorandapigeninasrdrpinhibitorinnimbamritadipanchatiktamkashayamagainstcovid19aninsilicoandinvitroapproach